2021³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2021-06-11±³À°ÀÏÀÚ : 2021-06-11
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë
±³À°ÁÖÁ¦ :
2021³â ´ëÇѽɺÎÀüÇÐȸ ÇÏ°è ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ
´ã´çÀÚ : ÀÌÀçÈñ
¿¬¶ôó : 02-3275-5335
À̸ÞÀÏ :
khfs@khfs.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 80¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 5 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 09:00~09:15 Benefit of Early Use of Ivabradine with Beta-blocker ±èÇüÀ±(Àü³²ÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 09:15~09:30 Is ARNI to be Top Priority in Prehospital-discharge Period? ¾ÈÈ¿¼®(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 09:30~09:45 Who Is Best Candidate for MRA with Concomittent SGLT2I? ±èÀÎö(°è¸íÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 09:45~10:00 Escape Strategy from Loop Diuretics Resistant ADHF Á¤¹ÌÇâ(ÇѸ²ÀÇ´ë)
Åä·Ð 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 10:00~10:20 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 10:20~10:40 Coffee Break ()
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 10:40~10:55 Recent Anemia Control in HF Àå¼¼¿ë(°æºÏÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 10:55~11:10 Two-sided Face of Chonic Kidney Disease on HF ¹ÚÁøÁÖ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 11:10~11:25 Is Atrial Fibrillation Device Therapy Really Beneficial in HFrEF? ±èÁø¹è(°æÈñÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 11:25~11:40 Is Diabetic Cardiomyopathy Real? ÀÌÂùÁÖ(¿¬¼¼ÀÇ´ë)
Åä·Ð 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 11:40~12:00 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 12:00~12:50 Lunch Time ()
ÈÞ½Ä 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 12:50~13:00 Break for Quarantine ()
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 13:00~13:15 Concomitant Valve Surgery during LVAD Implantation À̼ö¿ë(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 13:15~13:30 Quality of Life with an LVAD ¿ÀÀç¿ø(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 13:30~13:45 Primary Graft Dysfunction after Heart Transplantation Á¤¼ºÈ£(¿ï»êÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 13:45~14:00 Heart Transplantation Bridged with LVAD ±è°æÈñ(ÀÎõ¼¼Á¾º´¿ø)
Åä·Ð 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 14:00~14:20 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)
ÈÞ½Ä 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 14:20~14:40 Coffee Break ()
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 14:40~15:10 Plenary Session. Honored HF Specialist 伺ö(°æºÏÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 15:10~15:25 Case 1 ÀÌÁÖÈñ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 15:25~15:40 Case 2 Á¶Àͼº(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 15:40~15:55 Case 3 ±è¹Ì³ª(°í·ÁÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 15:55~16:10 Case 4 Á¤Çý¹®(°æÈñÀÇ´ë)
±³À°½Ã°£ 06-11 ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼¿ï Æĸ£³ª½º 2Ãþ ±¹È·ë 16:10~16:30 Discussion ´Ù°»ç(´Ù¼Ò¼Ó)